{"id":"a6a05bd2-0df7-4638-8e23-702a6fb29dbb","name":"Science Corp","slug":"science-corp","description":"Science Corporation is an Alameda-based neural engineering company developing biohybrid brain-computer interfaces. Its [PRIMA BCI](/models/prima-bci) retinal implant was the first treatment to restore form vision to patients blinded by late-stage macular degeneration, with results published in NEJM. CE Mark received July 2026 for European commercial launch. Total funding: 90M.","status":null,"founded":2021,"hq":"Alameda, California, USA","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"science.xyz","fundingTotal":"490000000","type":"both","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://science.xyz/news/series-c/","title":"Science Closes $230 Million Series C to Fund Commercialization of PRIMA BCI","sourceName":"Science Corporation"}],"keyFacts":[{"label":"Funding","value":"$490M total ($230M Series C)"},{"label":"Product","value":"PRIMA BCI retinal implant"},{"label":"Founder","value":"Max Hodak (ex-Neuralink)"},{"label":"Investors","value":"Khosla, Lightspeed, YC, IQT"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:32:34.383Z","updatedAt":"2026-08-08T22:41:01.391Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/science-corp","url":"https://registry.deploy.report/companies/science-corp","name":"Science Corp","description":"Science Corporation is an Alameda-based neural engineering company developing biohybrid brain-computer interfaces. Its [PRIMA BCI](/models/prima-bci) retinal implant was the first treatment to restore form vision to patients blinded by late-stage macular degeneration, with results published in NEJM. CE Mark received July 2026 for European commercial launch. Total funding: 90M.","identifier":"a6a05bd2-0df7-4638-8e23-702a6fb29dbb","foundingDate":"2021","address":"Alameda, California, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}